DOCSLIB.ORG

Rhode Island Early Intervention ICD-9 and ICD-10 CODES ESTABLISHED CONDITIONS LIST and SIGNIFICANT DEVELOPMENTAL DELAY

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rhode Island Early Intervention ICD-9 and ICD-10 CODES ESTABLISHED CONDITIONS LIST and SIGNIFICANT DEVELOPMENTAL DELAY Rhode Island Early Intervention ICD-9 and ICD-10 CODES ESTABLISHED CONDITIONS LIST AND SIGNIFICANT DEVELOPMENTAL DELAY All children diagnosed with established conditions that have a high probability of resulting in developmental delay, are eligible for early intervention services until the child’s third birthday, unless a change in the status of a diagnosis or condition resolves with medical/surgical treatment. Diagnosis must be made by a physician or other appropriately licensed professional and documentation of medical diagnosis is required. If a medical diagnosis or condition is not included in the RI Early Intervention Established Conditions List and it is a condition associated with developmental delay, approval for its use as Single Established Condition by the Lead Agency is required. Conditions listed with an asterisk * may be used only in determining initiial eligibility and require eligibilty to be re-determined in 1 year. These children must meet the criteria for Significant Developmental Delay at that time or be diagnosed with another qualifying condition. Conditions include but are not limited to the following listing. ICD-9 codes with an x indicate that the condition has several types. Additional digits for the specific type are required. SENSORY CONDITIONS CENTRAL NERVOUS SYSTEM DISORDERS (Continued) BLINDNESS 742.2 Q04.3 Lissencephaly 369.00 H54.0 Blindness, both eyes 322.9 G03.9 Meningitis with negative long-term effects 369.60 H54.40 Blindness, one eye 742.1 Q02 Microcephaly 377.75 H47.619 Cortical Blindness/Cortical Vision Impairment 292.0 *P96.1 Neonatal Abstinence Syndrome 377.10 H47.20 Optic Nerve Atrophy 742.2 Q04.3 Polymicrogyria 362.21 *H35.109 Retinopathy of Prematurity 780.39 R56.9 Seizure disorder (repetitive, recurrent) LOW VISION 345.60 G40.xxx Spasms, infantile 369.20 H54.2 Low vision, both eyes 741.00 Q05.4 Spina bifida with hydrocephalus (20/70 best acuity with correction) 741.90 Q05.8 Spina bifida without mention of hydrocephalus 369.70 *H54.50 Low vision, one eye 767.4 P11.5 Spinal Cord Injury at birth HEARING LOSS (permanent) 952.9 S14.109A Spinal Cord Injury not at birth 389.9 H91.93 Hearing impairment, bilateral 741.90 Q05.8 Spinal Lipomeningocele 389.9 H91.90 Hearing impairment, unilateral 759.6 Q85.8 Sturge-Weber disease 389.12 H90.5 Neural hearing loss/auditory neuropathy CHROMOSOMAL DISORDERS CANCERS 429.3 Q93.4 Cat Cry Syndrome (Cri-du-Chat) 199.1 C80.1 Cancer, Other (not included on this list) 758.x Q90.xx Chromosomal Anomaly (including Trisomies, 208.90 C91-95x Leukemia Deletions, Duplications, Translocations, 202.80 C83.7x Lymphoma Inversions, Rings and Isochromosome) 191.9 C71.9 Malignant neoplasm of brain Exceptions: Klinfelter’s Syndrome, Turner Syndrome) 189.0 C64.9 Malignant neoplasm of kidney 759.8 Q87.1 Cornelia De Lange Syndrome 170.9 C41.9 Osteosarcoma 758.0 Q90.9 Down Syndrome 171.4 C49.3 Rhabdomyosarcoma 759.83 Q99.2 Fragile X Syndrome CARDIAC CONDITIONS 759.81 Q87.1 Prader-Willi Syndrome 745.69 Q21.2 Atrioventricular canal defect 758.33 Q93.88 Smith-Magenis Syndrome 425.x Cardiomyopathy METABOLIC DISORDERS 747.1 Q25.1 Coarctation of the aorta 270.6 E72.20 Disorders of urea cycle metabolism 416.0 I27.0 Hypertension, pulmonary 270.9 E72.9 Amino acid metabolism disorder 746.7 Q23.4 Hypoplastic left heart syndrome 272.6 E88.1 Congenital lipodystrophy 746.9 Q24.9 Major cardiac anomaly, other (not included on this list) 271.1 *E74.21 Galactosemia 745.2 Q21.3 Tetralogy of Fallot 330.1 E75.19 Gangliosidosis 745.10 Q20.3 Transposition of great vessels 271.0 E74.00 Glycogen storage disease CENTRAL NERVOUS SYSTEM DISORDERS 277.5 E76.01 Hurler Syndrome 759.89 Q04.0 Aicardi syndrome 275.3 E83.39 Hypophosphatasia 740.0 Q00.0 Anencephaly 277.85 E71.310 LCHAD (Long Chain Acyl CoA Dehydrogenase Deficiency) 334.8 G11.3 Ataxia-Telangiectasia 270.3 *E71.0 Maple syrup urine disease/Methylmalonic acidemia 742.4 Q04.8 Brain Sclerosis 759.8 E83.09 Menkes Syndrome 335.22 G12.22 Bulbar palsy 277.5 E76.3 Mucopolysaccharidosis 742.4 Q04.8 Cerebral atrophy, congenital 271.8 E74.8 Other specified disorders of carbohydrate transport 343.9 G80.x Cerebral palsy and metabolism 436.9 I61.9 Cerebrovascular accident (CVA) 270.7 E72.3 Propionic acidemia 742.4 Q04.6 Congenital Schizencephaly 757.1 Q87.1 Sjogren-Larsson Syndrome 742.3 Q03.1 Dandy-Walker malformation 330.1 E75.02 Tay-Sachs disease 343.0 G80.1 Diplegia SKELETAL DISORDERS 323.9 G04.90 Encephalitis 714.30 M08.00 Arthritis, juvenile rheumatoid 742.0 Q01.9 Encephalocele 754.89 Q74.3 Arthrogryposis 348.30 G93.4 Encephalopathy 757.39 Q82.8 Beals Syndrome 345.90 G40.9xx Epilepsy 755.59 Q74.0 Cleidocranial Dysostosis 342.90 G81.90 Hemiparesis/Hemiplegia 756.0 Q75.0 Craniostenosis 742.2 Q04.02 Holoprosencephaly/Hypoplasia of the brain 756.0 Q75.9 Crouzon's Syndrome 742.3 Q04.3 Hydranencephaly 352.6 Q87.0 Mobius sequence 345.60 G40.8xx Hypsarrhythmia 756.0 Q75.0 Nager-de Reynier Syndrome 772.13 P52.21 Intraventricular hemorrhage (grade 3 ) 756.51 Q78.0 Osteogenesis imperfecta 772.14 P52.22 Intraventricular hemorrhage (grade 4) 755.30 Q68.8 Proximal Focal Femoral Deficiency (PFFD w/fibula hemimelia) 330.0 E75.25 Leukodystrophy/Canavan disease 754.89 *Q68.1 Radial Club Hand October 2015 ICD-9/ICD10 Codes Established Conditions List and Developmental Delay Rev Feb 2016 ICD-9 and ICD-10 CODES ESTABLISHED CONDITIONS LIST OTHER DISORDERS OTHER DISORDERS (Continued) 755.4 Q73.0 Absence of limb 771.0 P35.00 Rubella, congenital 756.4 Q77.4 Achondroplasia 754.2 M41.00 Scoliosis (congenital, severe) 658.8 *P02.8 ADAM Complex 754.1 *Q68.0 Torticollis, congenital 042 B20 AIDS 771.2 P37.1 Toxoplasmosis, congenital 284.9 D61.9 Aplastic anemia 854.00 S09.8XXS Traumatic Head Injury 299.00 F84.0 Autism 759.5 Q85.1 Tuberous Sclerosis 749.20 *Q37.9 Cleft lip and palate 749.00 *Q35.9 Cleft palate OTHER SYNDROMES 771.1 P35.1 Congenital CMV - Cytomegalovirus 759.89 Q44.7 Alagille Syndrome 759.4 Q89.4 Conjoined twin 759.89 Q93.5 Angelman Syndrome 277.0x E84.x Cystic fibrosis 755.55 Q87.0 Apert Syndrome 259.4 E34.3 Dwarfism 299.80 F84.5 Asperger Syndrome 757.39 Q81.9 Epidermolysis Bullosa 759.89 Q87.3 Beckwith-Wiedemann Syndrome 767.6 P14.0 Erb's palsy (Brachial Plexis injury) 284.01 D61.0 Blackfan-Diamond Syndrome 783.41 *R62.51 Failure to Thrive 757.33 Q82.3 Bloch-Sulzberger Syndrome 284.09 D61.09 Fanconi Anemia 758.3 Q92.8 Cat Eye Syndrome 307.59 F98.29 Feeding Disorder 759.89 Q89.8 CHARGE Syndrome 756.79 Q79.3 Gastroschisis 759.89 Q87.1 Cockayne Syndrome 754.0 Q67.4 Hemifacial Microsomia 279.11 D82.1 DiGeorge Syndrome 771.2 *P35.2 Herpes, congenital 756.83 Q79.6 Ehlers-Danlos Syndrome G91.xx Hydrocephalus 448.1 I78.1 Epidermal Nevus Syndrome 778.0 P83.2 Hydrops-Fetalis 581.9 N04.9 Epstein's Syndrome 243 E00.9 Hypothyroidism, congenital 760.71 P04.3 Fetal Alcohol Syndrome 774.7 P57.8 Kernicterus 756.0 Q87.0 Goldenhar Syndrome 984.9 *T56.OX1A Lead Poisoning (15 mg/dl venous lead level or greater) 756.16 Q76.1 Klippel-Feil Syndrome 330.8 G31.82 Leigh's Disease 755.8 Q74.8 Larsen Syndrome 573.9 K76.9 Liver disease and/or dysfunction 759.89 Q87.1 Noonan Syndrome 765.01 *P07.01 Very Low Birth Weight <500 grams 756.0 *Q75.9 Pierre Robin Syndrome 765.02 *P07.02 Very Low Birth Weight 500-749 grams 760.70 *Q86.1 Fetal Hydantoin Syndrome 765.03 *P07.03 Very Low Birth Weight 750-999 grams 299.90 F84.9 Rett Syndrome 765.04 *P07.14 Very Low Birth Weight 1000-1250 grams 759.89 Q87.2 Rubinstein-Taybi Syndrome 765.05 *P07.15 Very Low Birth Weight 1250-1499 grams 759.89 Q87.1 Russell-Silver Syndrome 756.9 Q78.5 Metaphyseal dysplasia 995.55 T74.4XXs Shaken Baby Syndrome 277.9 E88.9 Mitochondrial myopathy 759.89 E78.72 Smith-Lemli-Optiz Syndrome 437.5 I67.5 Moyamoya disease 253.0 E22.0 Sotos Syndrome 359.x G71.0 Muscular dystrophy/Duchenne's 759.89 Q87.8 Stickler Syndrome (includes progressive muscular atrophy) 756.0 Q75.4 Treacher Collins Syndrome 742.59 Q06.8 Myelodysplasia 759.89 Q87.2 VACTER Syndrome 359.21 G71.11 Myotonic dystrophy 270.2 E70.3 Waardenburg-Klein Syndrome 237.70 Q85.00 Neurofibromatosis 759.89 Q93.8 Williams Syndrome 478.30 J38.00 Paralysis, vocal cords 279.12 D82.0 Wiskott-Aldrich Syndrome 299.80 F84.8 Pervasive Developmental Disorder (PDD) ICD-9 and ICD-10 CODES SIGNIFICANT DEVELOPMENTAL DELAY Children with Significant Developmental Delay are eligible for early intervention services until their third birthday unless there is a change in functioning. When there has been significant progress and whenever eligibility is questioned a multidisciplinary evaluation/assessment to redetermine eligibility must occur. The ICD-9 codes below are used for children eligible for early intervention due to significant developmental delay. SPECIFIC DELAYS IN DEVELOPMENT 315.31 F80.1 Expressive language disorder (Expressive language delay) 315.9 F88 Other disorders of psychological development 315.32 F80.2 Mixed expressive receptive language disorder (Developmental disorder, Global developmental delay; (Receptive language delay, Expressive/receptive Developmental delay cognitive; Sensory Integration language disorder) Disorder) 315.39 F80.89 Other developmental disorders of speech and language 315.9 Deleted: Unspecified delay in development 315.4 F82 Specific development disorder of motor function 783.42 R62.0 Delayed Milestones (Clumsiness, Motor delay; Gross motor (Delayed developmental milestones; delayed speech development delay, Fine motor delay, milestones; delayed milestone, late walker, late talker ) Neuromuscular disorder) 315.4 Deleted: Developmental coordination disorder (F82) R63.3 Feeding Difficulties 315.5 Deleted: Mixed development disorder (See F82) (Developmental delay in feeding) 315.8 Deleted: Other specific delays in development(See F88) 783.9 Deleted: Other symtoms concerning nutrition, October 2015 ICD-9/ICD10 Codes Established Conditions List and Developmental Delay Rev Feb 2016 metabolism and development (See R63.3) October 2015 ICD-9/ICD10 Codes Established Conditions List and Developmental Delay Rev Feb 2016.
Load more

Recommended publications
  • Megalencephaly and Macrocephaly
    277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ►
    [Show full text]
  • The First Non-Invasive Prenatal Test That Screens for Single-Gene Disorders
    The first non-invasive prenatal test that screens for single-gene disorders the evolution of NIPT A non-invasive prenatal test that screens multiple genes for mutations causing severe genetic disorders in the fetus analyses circulating cell- free fetal DNA (cfDNA) from a maternal blood sample. The test is performed after 10 weeks of pregnancy. works as a complementary screen to traditional and genome- wide NIPT . It screens for several life-altering genetic disorders that are not screened with current NIPT technology, allowing a complete picture of the risk of a pregnancy being affected by a genetic disorder. 2 facilitates early diagnosis of single-gene disorders. It involves 3 different levels of screening: This test screens for 5 common inherited recessive genetic disorders, such as Cystic Fibrosis, Beta-Thalassemia, Sickle INHERITED cell anaemia, Deafness autosomal recessive type 1A, Deafness autosomal recessive type 1B. Genes screened: CFTR, CX26 (GJB2), CX30 (GJB6), HBB This test screens for 44 severe genetic disorders due to de novo mutations (a gene mutation that is not inherited) in 25 genes DE NOVO Genes screened: ASXL1, BRAF, CBL, CHD7, COL1A1, COL1A2 , COL2A1, FGFR2, FGFR3, HDAC8, JAG1, KRAS, MAP2K1, MAP2K2, MECP2, NIPBL, NRAS, NSD1, PTPN11, RAF1, RIT1, SETBP1, SHOC2, SIX3, SOS1 This test screens for both inherited and de novo single-gene disorders and represents a combination of the tests INHERITED COMPLETE and DE NOVO providing a complete picture of the pregnancy risk. 3 allows detection of common inherited genetic disorders in INHERITED the fetus GENE GENETIC DISORDER CFTR Cystic Fibrosis CX26 (GJB2) Deafness autosomal recessive type 1A CX30 (GJB6) Deafness autosomal recessive type 1B HBB Beta-Thalassemia HBB Sickle cell anemia The inherited recessive disorders screened by INHERITED are the most common in the European population 4 identifies fetal conditions that could be missed by traditional DE NOVO prenatal screening.
    [Show full text]
  • Metacarpophalangeal Pattern Profile Analysis in Sotos Syndrome
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by IUPUIScholarWorks Author manuscript Author ManuscriptAuthor Manuscript Author Am J Med Manuscript Author Genet. Author Manuscript Author manuscript; available in PMC 2017 September 12. Published in final edited form as: Am J Med Genet. 1985 April ; 20(4): 625–629. doi:10.1002/ajmg.1320200408. Metacarpophalangeal Pattern Profile Analysis in Sotos Syndrome Merlin G. Butler, Department of Biology, University of Notre Dame and North Central Regional Genetics Center, Memorial Hospital, South Bend, Indiana Department of Medical Genetics, Indiana University School of Medicine F. John Meaney, Department of Medical Genetics, Indiana University School of Medicine Genetic Diseases Section, Indiana State Board of Health, Indianapolis Smita Kittur, Pediatric Genetics Department, Children’s Medical and Surgical Center, Johns Hopkins Hospital, Baltimore Joseph H. Hersh, and Child Evaluation Center, Department of Pediatrics, University of Louisville School of Medicine Lusia Hornstein Cincinnati Center for Developmental Disorders, Children’s Hospital Medical Center Abstract The metacarpophalangeal pattern profile (MCPP) was analyzed on 16 Sotos syndrome patients. A mean Sotos syndrome profile was produced. Correlation studies confirm clinical homogeneity of Sotos syndrome individuals. Discriminant analysis of Sotos syndrome patients and normal individuals produces a function of two MCPP variables and age, which may provide a useful tool for diagnosis. Keywords Sotos syndrome; metacarpophalangeal pattern profile (MCPP); discriminant analysis; correlation studies INTRODUCTION Sotos syndrome, or cerebral gigantism, was first described by Sotos et al [1964]; at least 100 cases were reported subsequently. This syndrome is characterized by large size at birth, large hands and feet, advanced osseous maturation, macrocephaly with prominent forehead and Address reprint requests to Merlin G.
    [Show full text]
  • Diagnostic Utility of Genome-Wide DNA Methylation Analysis in Mendelian Neurodevelopmental Disorders
    International Journal of Molecular Sciences Review Diagnostic Utility of Genome-Wide DNA Methylation Analysis in Mendelian Neurodevelopmental Disorders Sadegheh Haghshenas 1,2 , Pratibha Bhai 2, Erfan Aref-Eshghi 3 and Bekim Sadikovic 1,2,4,* 1 Department of Pathology and Laboratory Medicine, Western University, London, ON N6A 3K7, Canada; [email protected] 2 Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A 5W9, Canada; [email protected] 3 Division of Genomic Diagnostics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; [email protected] 4 Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada * Correspondence: [email protected] Received: 22 November 2020; Accepted: 4 December 2020; Published: 6 December 2020 Abstract: Mendelian neurodevelopmental disorders customarily present with complex and overlapping symptoms, complicating the clinical diagnosis. Individuals with a growing number of the so-called rare disorders exhibit unique, disorder-specific DNA methylation patterns, consequent to the underlying gene defects. Besides providing insights to the pathophysiology and molecular biology of these disorders, we can use these epigenetic patterns as functional biomarkers for the screening and diagnosis of these conditions. This review summarizes our current understanding of DNA methylation episignatures in rare disorders and describes the underlying technology and analytical approaches. We discuss the computational parameters, including statistical and machine learning methods, used for the screening and classification of genetic variants of uncertain clinical significance. Describing the rationale and principles applied to the specific computational models that are used to develop and adapt the DNA methylation episignatures for the diagnosis of rare disorders, we highlight the opportunities and challenges in this emerging branch of diagnostic medicine.
    [Show full text]
  • Regional Genetic Consultation Service
    Regional Genetic Consultation Service Contract 5889BD01 July 1, 2018 through June 30, 2019 Congenital & Inherited Disorders Division of Health Promotion & Chronic Disease Prevention, Phone: 1-800-383-3826 http://idph.iowa.gov/genetics Regional Genetic Consultation Service: A contract established by IDPH in the Division of Health Promotion & Chronic Disease Prevention, Contract # 5888BD01 Administrative Code, Chapter 4:641-4.5(136A) Iowa Department of Public Health Advancing Health Through the Generations Kimberly Reynolds Adam Gregg Gerd Clabaugh Governor Lt. Governor Director Authorized State Official for this contract: Brenda Dobson, Director, Division of Health Promotion and Chronic Disease Prevention (515) 281-7769 University of Iowa Stead Family Department of Pediatrics (319) 356-2675 Hatem El-Shanti, MD, Division Director John A. Bernat, MD, PhD, Clinical Director Hannah Bombei, MS, CGC, Program Coordinator Page | 2 Congenital & Inherited Disorders Division of Health Promotion & Chronic Disease Prevention, Phone: 800-383-3826 http://idph.iowa.gov/genetics In collaboration with the Iowa Department of Public Health & The Stead Family Department of Pediatrics Division of Medical Genetics & Genomics University of Iowa Stead Family Children’s Hospital & Clinical Outreach Services University of Iowa Hospitals and Clinics Page | 3 What is the Regional Genetic Consultation Service? Iowa Administrative Code 641—4.5(136A) Regional Genetic Consultation Service (RGCS). This program provides comprehensive genetic and genomic services statewide through outreach clinics. 4.5(1) Provision of comprehensive genetic and genomic services. The department shall contract with the Division of Medical Genetics & Genomics within the Stead Family Department of Pediatrics at the University of Iowa to provide genetic and genomic health care and education outreach services for individuals and families within Iowa.
    [Show full text]
  • Abstracts Books 2014
    TWENTY-FIFTH EUROPEAN MEETING ON DYSMORPHOLOGY 10 – 12 SEPTEMBER 2014 25th EUROPEAN MEETING ON DYSMORPHOLOGY LE BISCHENBERG WEDNESDAY 10th SEPTEMBER 5 p.m. to 7.30 p.m. Registration 7.30 p.m. to 8.30 p.m. Welcome reception 8.30 p.m. Dinner 9.30 p.m. Unknown THURSDAY 11th SEPTEMBER 8.15 a.m. Opening address 8.30 a.m. to 1.00 p.m. First session 1.00 p.m. Lunch 2.30 p.m. to 7.00 p.m. Second and third sessions 8.00 p.m. Dinner 9.00 p.m. to 11.00 p.m. Unknown FRIDAY 12th SEPTEMBER 8.30 a.m. to 1.00 p.m. Fourth and fifth sessions 1.00 p.m. Lunch 2.30 p.m. to 6.00 p.m. Sixth and seventh sessions 7.30 p.m. Dinner SATURDAY 13th SEPTEMBER Breakfast – Departure Note: This program is tentative and may be modified. WEDNESDAY 10th SEPTEMBER 9.30 UNKNOWN SESSION Chair: FRYNS J.P. H. VAN ESCH Case 1 H. VAN ESCH Case 2 H. JILANI, S. HIZEM, I. REJEB, F. DZIRI AND L. BEN JEMAA Developmental delay, dysmorphic features and hirsutism in a Tunisian girl. Cornelia de Lange syndrome? L. VAN MALDERGEM, C. CABROL, B. LOEYS, M. SALEH, Y. BERNARD, L. CHAMARD AND J. PIARD Megalophthalmos and thoracic great vessels aneurisms E. SCHAEFER AND Y. HERENGER An unknown diagnosis associating facial dysmorphism, developmental delay, posterior urethral valves and severe constipation P. RUMP AND T. VAN ESSEN What’s in the name G. MUBUNGU, A. LUMAKA, K.
    [Show full text]
  • Jaw Keratocysts and Sotos Syndrome
    International Journal on Oral Health Jaw Keratocysts and Sotos Syndrome Case Report Volume 1 Issue 2- 2021 Author Details Jin Fei Yeo and Philip McLoughlin* Faculty of Dentistry, National University Centre for Oral Health Singapore, Singapore *Corresponding author Philip McLoughlin, Discipline of Oral & Maxillofacial Surgery, Faculty of Dentistry, National University Centre for Oral Health Singapore, 9 Lower Kent Ridge Road, Singapore Article History Received: June 05, 2021 Accepted: June 14, 2021 Published: June 15, 2021 Abstract Sotos syndrome, described by Sotos et al. [1], is characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. The disorder is largely caused by mutations or deletions in the NSD1 gene. The typical facial gestalt includes macrodolichocephaly with frontal bossing, front-parietal sparseness of hair, apparent hypertelorism, down slanting palpebral in his jaw bones, a previously unreported oral manifestation, out with a syndromic context. fissures, and facial flushing. This paper discusses a case of Sotos syndrome in an adolescent male with multiple odontogenic keratocysts Introduction On examination, he was a generally healthy and rather active patient. He was very tall with macrocephaly, large hands and feet, and Sotos syndrome (Cerebral gigantism) is a rare genetic childhood hypertelorism with slightly down-slanted eyes. He also suffered ASD/ overgrowth condition described in 1964 by Sotos et al. [1]. This autism and mild mental hypo development with noticeable speech syndrome is characterized by excessive growth during childhood, impairment. On clinical assessment he was found to have a number of macrocephaly, distinctive facial appearance and learning disability. unerupted teeth, with fluctuant expansion of the maxilla and mandible The disorder is caused by mutations or 5q35 microdeletions in the at those sites.
    [Show full text]
  • Soonerstart Automatic Qualifying Syndromes and Conditions
    SoonerStart Automatic Qualifying Syndromes and Conditions - Appendix O Abetalipoproteinemia Acanthocytosis (see Abetalipoproteinemia) Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) Acidemia, 2-Oxoglutaric Acidemia, Glutaric I Acidemia, Isovaleric Acidemia, Methylmalonic Acidemia, Propionic Aciduria, 3-Methylglutaconic Type II Aciduria, Argininosuccinic Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) Acrocephalopolysyndactyly Type II Acrocephalosyndactyly Type I Acrodysostosis Acrofacial Dysostosis, Nager Type Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) Aglossia Congenita (see Hypoglossia-Hypodactylia) Aicardi Syndrome AIDS Infection (see Fetal Acquired Immune Deficiency Syndrome) Alaninuria (see Pyruvate Dehydrogenase Deficiency) Albers-Schonberg Disease (see Osteopetrosis, Malignant Recessive) Albinism, Ocular (includes Autosomal Recessive Type) Albinism, Oculocutaneous, Brown Type (Type IV) Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) Albinism, Oculocutaneous, Tyrosinase Positive (Type II) Albinism, Oculocutaneous, Yellow Mutant (Type IB) Albinism-Black Locks-Deafness Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) Alexander Disease Alopecia - Mental Retardation Alpers Disease Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) Alpha-L-Fucosidase Deficiency (see Fucosidosis) Alport Syndrome (see Nephritis-Deafness, Hereditary Type) Amaurosis (see Blindness) Amaurosis
    [Show full text]
  • Workshop Schedule
    Workshop Schedule Friday, August 27th Registration: 4:00‐6:30 pm Dinner 6:30‐8:00 pm Reception 8:00‐10:00 Saturday, August 28th 7:00‐8:15 am Breakfast: 8:15am Welcome and Introductions 8:30‐10:15 am Session 1: Novel strategies to understand the causes/mechanisms of birth defects (Moderator: Angela Lin) 8:30 am Les Biesecker ‐ Using massively parallel sequencing technologies to provide improved molecular delineation of human malformation syndromes 9:15 am Bamshad ‐ Exome sequencing identifies a gene for Kabuki syndrome 9:30 am Boycott ‐ Next‐Generation sequencing strategies give insight into the mechanism of birth defects in a Canadian isolated population 9:45 am Bleyl ‐ Comparison of pooled allelic ratios (CoPAR) analysis: an efficient method for mapping genetic traits in extended pedigrees 10:00 am Allanson – Nablus mask‐like facial syndrome and blepharo‐naso‐facial syndrome are the same entity. Refinement of the critical region of chromosome 8q22.1 points to a potential candidate gene 10:15‐10:45 am BREAK 10:45‐12:00 pm Session 2: Novel strategies to understand the causes/mechanisms of birth defects (cont.) (Moderator: Mike Bamshad) 10:45 am Krantz ‐ Applying novel genomic tools towards understanding an old chromosomal diagnosis: Using genome‐wide expression and SNP genotyping to identify the true cause of Pallister‐Killian syndrome 11:00 am Paciorkowski ‐ Bioinformatic analysis of published and novel copy number variants suggests candidate genes and networks for infantile spasms 11:15 am Bernier ‐ Identification of a novel Fibulin
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]
  • Craniosynostosis Precision Panel Overview Indications Clinical Utility
    Craniosynostosis Precision Panel Overview Craniosynostosis is defined as the premature fusion of one or more cranial sutures, often resulting in abnormal head shape. It is a developmental craniofacial anomaly resulting from a primary defect of ossification (primary craniosynostosis) or, more commonly, from a failure of brain growth (secondary craniosynostosis). As well, craniosynostosis can be simple when only one suture fuses prematurely or complex/compound when there is a premature fusion of multiple sutures. Complex craniosynostosis are usually associated with other body deformities. The main morbidity risk is the elevated intracranial pressure and subsequent brain damage. When left untreated, craniosynostosis can cause serious complications such as developmental delay, facial abnormality, sensory, respiratory and neurological dysfunction, eye anomalies and psychosocial disturbances. In approximately 85% of the cases, this disease is isolated and nonsyndromic. Syndromic craniosynostosis usually present with multiorgan complications. The Igenomix Craniosynostosis Precision Panel can be used to make a directed and accurate diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. Indications The Igenomix Craniosynostosis Precision Panel is indicated for those patients with a clinical diagnosis or suspicion with or without the following manifestations: ‐ Microcephaly ‐ Scaphocephaly (elongated head) ‐ Anterior plagiocephaly ‐ Brachycephaly ‐ Torticollis ‐ Frontal bossing Clinical Utility The clinical utility of this panel is: - The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. - Early initiation of treatment in the form surgical procedures to relieve fused sutures, midface advancement, limited phase of orthodontic treatment and combined 1 orthodontics/orthognathic surgery treatment.
    [Show full text]
  • Vistara Non-Invasive Prenatal Screen
    Vistara non-invasive prenatal screen Hypochondro- Causes a mild form of dwarsm; up to 80% Vistara identies probability for conditions that may have otherwise gone undetected until after birth plasia may cause seizures with secondary or into childhood. All conditions are inherited in an autosomal or X-linked dominant fashion, which means that FGFR3 developmental delay if the mutation is present, the child will be affected by the condition and experience related symptoms. Intellectual Causes intellectual disability and ~100% disability developmental delays SYNGAP1 Condition1 Clinical Cases Ultrasound ndings2,3 Clinical Detection Gene(s) synopsis2,3 caused by actionability rate for Jackson Weiss A type of craniosynostosis; more de novo None Third Non- gene1 syndrome also causes foot abnormalities severe mutations2,3 trimester specic FGFR2 forms Achondroplasia The most common form 80% Labor and delivery >96% FGFR3 of skeletal dysplasia; may management, monitor Juvenile A rare pediatric blood cancer; ve- unknown cause hydrocephalus, for spinal stenosis, early myelomonocytic year survival is approximately 50% delayed motor milestones, sleep studies to reduce leukemia (JMML) and spinal stenosis risk of SIDS PTPN11 Alagille Affects multiple organ systems 50% to 70% Symptom-based >86% LEOPARD Similar to Noonan syndrome, unknown syndrome and may cause growth problems, treatment syndrome 1,2 with notable brown skin spots JAG1 congenital heart defects, and (Noonan (lentigines); causes short stature, vertebral differences syndrome heart defects, bleeding
    [Show full text]